Cited by 463Acute Myeloid Leukemia ResearchCancer-related Molecular PathwaysRetinoids in leukemia and cellular processes

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, Martin, Saft, Leonie, Smith, Alexander, Kulasekararaj, Austin, Pomplun, Sabine, Göhring, Gudrun, Hedlund, Anette, Hast, Robert, Schlegelberger, Brigitte, Porwit, Anna, Hellström-Lindberg, Eva, Mufti, Ghulam J.·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.31.8576

Open this paper in CoChat — free account

Abstract

Purpose: To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression. Patients and Methods: Pre- and postprogression bone marrow (BM) samples from 55 consecutive patients with International Prognostic Scoring System low risk (n = 32) or intermediate-1 risk (n = 23) were studied by next-generation sequencing of TP53. IHC for p53 was performed on 148 sequential BM samples. Results: TP53 mutations with a median clone size of 11% (range, 1% to 54%) were detected in 10 patients (18%) already at an early phase of the disease. Mutations were equally common in low-risk and intermediate-1–risk patients and were associated with evolution to acute myeloid leukemia (5 of 10 v 7 of 45; P = .045). Nine of 10 patients carrying mutations showed more than 2% BM progenitors with strong p53 staining. The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). Conclusion: By using sensitive deep-sequencing technology, we demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q). Importantly, mutations were present years before disease progression and were associated with an increased risk of leukemic evolution. TP53 mutations could not be predicted by common clinical features but were associated with p53 overexpression. Our findings indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.31.8576

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citation
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
Malcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome
Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 349
Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R. A., Guinn, B., Al-Sabah, A., Smith, M. T., Taylor, C., Pettersson, T., Ridge, S. A., Carter, G., White, D., Oscier, D. G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
Giagounidis, A. A. N., Germing, U., Haase, S. P., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H. P. J., Aivado, M. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 210
Self-citation
Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123

Show all 33 references

Research works printed but not linked: 9

Preudhomme C, 1994, Leukemia, 8, 2241
Lai JL, 1995, Leukemia, 9, 370
Kitagawa M, 1994, Am J Pathol, 145, 338
Ludwig L, 1992, Leukemia, 6, 1302
Fidler C, 2004, Haematologica, 89, 865
Fenaux P, 1990, Nouv Rev Fr Hematol, 32, 341
Lepelley P, 1994, Leukemia, 8, 1342
Ramos F, 2002, Haematologica, 87, 381
Orazi A, 1996, Mod Pathol, 9, 48

Sorted by citations

Items 201–300 of 462

Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML
Drulă, R., Iluta, S., Gulei, D., Iuga, C. A., Dima, D. M., Ghiaur, G., Buzoianu, A. D., Ciechanover, A. J., & Tomuleasa, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100971 · Cited by 20
TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches
Pereira, M. P., Herrity, E., & Kim, D. D. H. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05462-5 · Cited by 20
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Zeidan, A. M., Zahr, A. A., Aldin, E. S., & Komrokji, R. S. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s50482 · Cited by 20
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome
Poloni, A., Serrani, F., Berardinelli, E., Maurizi, G., Mariani, M., Costantini, B., Trappolini, S., Mancini, S., Olivieri, A., & Leoni, P. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.022 · Cited by 21
Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing
Kohlmann, A., Bacher, U., Schnittger, S., & Haferlach, T. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.856427 · Cited by 20
Important Genes in the Pathogenesis of 5q- Syndrome and Their Connection with Ribosomal Stress and the Innate Immune System Pathway
Fuchs, O. (2012) · Leukemia Research and Treatment · doi:10.1155/2012/179402 · Cited by 21
Myelodysplastic syndromes
Zhou, J., Orazi, A., & Czader, M. (2011) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2011.08.005 · Cited by 20
Evolving therapies for lower-risk myelodysplastic syndromes
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03963-1 · Cited by 19
Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 20
Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Palacios‐Berraquero, M. L., & Piérola, A. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102107 · Cited by 19
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Gurnari, C., Piciocchi, A., Soddu, S., Bonanni, F., Scalzulli, E., Niscola, P., Veroli, A. D., Piccioni, A. L., Piedimonte, M., Maiorana, G., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00724-3 · Cited by 21
Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Hart, S. A., Lee, L. A., Seegmiller, A. C., & Mason, E. F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014140 · Cited by 19
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee, E.-J., & Zeidan, A. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1016905 · Cited by 19
Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a “grey zone” combination of myelodysplastic and myeloproliferative features?
Sangiorgio, V. F. I., Geyer, J. T., Margolskee, E. M., Al‐Kawaaz, M., Mathew, S., Tam, W., & Orazi, A. (2019) · Haematologica · doi:10.3324/haematol.2019.227686 · Cited by 19
Myelodysplastic Syndromes
Odenike, O. M., Anastasi, J., & Beau, M. M. L. (2011) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2011.08.005 · Cited by 20
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.308 · Cited by 18
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
Duong, V. H., Komrokji, R. S., & List, A. F. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620711435659 · Cited by 20
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nardi, V., & Hasserjian, R. P. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.004 · Cited by 19
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Lewis, R., Bewersdorf, J. P., & Zeidan, A. M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s240600 · Cited by 17
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes
Schulz, E., Aplan, P. D., Freeman, S. D., & Pavletic, S. Z. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010098 · Cited by 17
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management
Burgstaller, S., Wiesinger, P., & Stauder, R. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0312-7 · Cited by 17
Multivariate time‐dependent comparison of the impact of lenalidomide in lower‐risk myelodysplastic syndromes with chromosome 5q deletion
Sánchez‐García, J., del Cañizo, C., Lorenzo, I., Nomdedeu, B., Luño, E., de Paz, R., Xicoy, B., Valcárcel, D., Brunet, S., Betes, V. M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12876 · Cited by 18
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
McGraw, K. L., Zhang, L. M., Rollison, D. E. M., Basiorka, A. A., Fulp, W. J., Rawal, B., Jerez, A., Billingsley, D., Lin, H.-Y., Kurtin, S. E., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.11 · Cited by 18
Self-citation
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Miltiades, P., Lamprianidou, E., Vassilakopoulos, T., Papageorgiou, S., Galanopoulos, A., Kontos, C., Adamopoulos, P., Nakou, E., Vakalopoulou, S., Garypidou, V., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1288 · Cited by 17
New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes
Haider, M., Duncavage, E. J., Afaneh, K. F., Bejar, R. L., & List, A. F. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175397 · Cited by 16
Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease
Stengel, A., Jeromin, S., Haferlach, T., Meggendorfer, M., Kern, W., & Haferlach, C. (2018) · Haematologica · doi:10.3324/haematol.2018.202952 · Cited by 16
The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes
Johansson, U., McIver‐Brown, N., Cullen, M. J., Duetz, C., Dunlop, A. S., Oelschlägel, U., Psarra, K., Subirá, D., & Westers, T. M. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22048 · Cited by 16
Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
Pellagatti, A., Fernández‐Mercado, M., Genua, C. D., Larráyoz, M. J., Killick, S. B., Dolatshad, H., Burns, A., Calasanz, M. J., Schuh, A., & Boultwood, J. (2013) · Leukemia · doi:10.1038/leu.2013.381 · Cited by 16
PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia
Guirguis, A. A., Slape, C. I., Failla, L. M., Saw, J., Tremblay, C. S., Powell, D., Rossello, F. J., Wei, A. H., Strasser, A., & Curtis, D. J. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.159 · Cited by 17
What lies beyond del(5q) in myelodysplastic syndrome?
Ademà, V., & Bejar, R. L. (2013) · Haematologica · doi:10.3324/haematol.2013.094912 · Cited by 17
Cytogenetic features in myelodysplastic syndromes
Schanz, J., & Haase, D. T. (2014) · doi:10.2217/fmeb2013.13.135 · Cited by 16
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
Zeidan, A. M., Bewersdorf, J. P., Hasle, V., Shallis, R. M., Thompson, E. G., Menezes, D. L. D., Rose, S., Boss, I. W., Halene, S., Haferlach, T., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241257904 · Cited by 16
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 15
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes
Voutsadakis, I. A., & Cairoli, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.623255 · Cited by 16
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
McGraw, K. L., Cluzeau, T., Sallman, D. A., Basiorka, A. A., Irvine, B. A., Zhang, L., Epling‐Burnette, P. K., Rollison, D. E. M., Mallo, M., Sokol, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5255 · Cited by 15
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll, P. S., Yoshizato, T., Hellström‐Lindberg, E., Fioretos, T., Ebert, B. L., & Jacobsen, S. E. W. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13535 · Cited by 15
Self-citation
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
Loschi, M. L., Fenaux, P., & Cluzeau, T. (2022) · Cancers · doi:10.3390/cancers14184519 · Cited by 16
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Ritchie, E. K. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s24659 · Cited by 15
BMT for Myelodysplastic Syndrome: When and Where and How
Jain, A. G., & Elmariah, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.771614 · Cited by 14
Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges
Bejar, R. L., Tiu, R. V., Sekeres, M. A., & Komrokji, R. S. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e256 · Cited by 15
Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights
Shahrabi, S., Khosravi, A., Shahjahani, M., Rahim, F., & Saki, N. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.311 · Cited by 14
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
Chan, O., Ali, N. E. A., Sallman, D. A., Padron, E., Lancet, J. E., & Komrokji, R. S. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.002 · Cited by 15
Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
Acha, P., Mallo, M., & Solé, F. G. (2022) · Cancers · doi:10.3390/cancers14225531 · Cited by 14
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes
Minetto, P., Guolo, F., Clavio, M., Astis, E. D., Colombo, N., Grasso, R., Fugazza, G., Sessarego, M., Lemoli, R. M., Gobbi, M., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.04.011 · Cited by 14
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Prébet, T., Charbonnier, A., Gelsi‐Boyer, V., Mozziconacci, M. J., Blaise, D., & Vey, N. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.744455 · Cited by 14
Improving Treatment for Myelodysplastic Syndromes Patients
Montoro, M. J., Yerlikaya, A., Ali, A. M., & Raza, A. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0583-4 · Cited by 14
British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes
Killick, S. B., Wiseman, D. H., Quek, L. S., Cargo, C. A., Culligan, D. J., Enright, H., Green, S., Ingram, W. A., Jones, G. L., Kell, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17621 · Cited by 14
Self-citation
Getting personal with myelodysplastic syndromes: is now the right time?
Chokr, N., Pine, A. B., Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1592673 · Cited by 13
Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age
Xie, Z., Chen, E. C., Stahl, M. F., & Zeidan, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101033 · Cited by 13
Treatment of Myelodysplastic Syndromes
Kurtin, S. E., Demakos, E. P., Hayden, J., & Boglione, C. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.s1.23-35 · Cited by 13
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring
Jädersten, M., & Karsan, A. (2011) · Haematologica · doi:10.3324/haematol.2010.038281 · Cited by 14
Self-citation
Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia: A case Series and Literature Review
Zeichner, S. B., Alghamdi, S., Elhammady, G., Poppiti, R., & Castellano-Sanchez, A. A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.4.1603 · Cited by 13
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., & Haferlach, C. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22377 · Cited by 13
TP53 Modulates Oxidative Stress in Gata1 + Erythroid Cells
Kramer, A. C., Weber, J. M., Zhang, Y., Tolar, J., Gibbens, Y., Shevik, M. E., & Lund, T. C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.025 · Cited by 14
Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
Poiré, X., Labopin, M., Polge, E., Forcade, É., Ganser, A., Volin, L., Michallet, M., Blaise, D., Yakoub‐Agha, I., Maertens, J. A., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.216168 · Cited by 13
The myelodysplastic syndromes: the era of understanding
Meers, S. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12443 · Cited by 14
A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics
Nishiwaki, S., Ito, M., Watarai, R., Okuno, S., Harada, Y., Yamamoto, S., Suzuki, K., Kurahashi, S., Iwasaki, T., & Sugiura, I. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.11.014 · Cited by 13
Application of Optical Genome Mapping For Comprehensive Assessment of Chromosomal Structural Variants for Clinical Evaluation of Myelodysplastic SyndromesPreprint
Yang, H., Garcia‐Manero, G., Rush, D. M., Bravo, G. M., Mallampati, S., Medeiros, L. J., Levy, B., Luthra, R., & Kanagal‐Shamanna, R. (2021) · medRxiv · doi:10.1101/2021.01.13.21249611 · Cited by 13
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
Frumm, S. M., Shimony, S. O., Stone, R. M., DeAngelo, D. J., Bewersdorf, J. P., Zeidan, A. M., & Stahl, M. F. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101056 · Cited by 12
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Garderet, L., Ziagkos, D., van Biezen, A., Iacobelli, S., Finke, J., Maertens, J. A., Volin, L., Ljungman, P. T., Chevallier, P., Passweg, J. R., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.11.017 · Cited by 12
Self-citation
Advances and challenges in the treatment of myelodysplastic syndromes
Thalla, R., Mack, R. M., Kosti, J., Breslin, P., & Zhang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00678-9 · Cited by 11
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
Toribio-Castelló, S., Castaño, S., Villaverde-Ramiro, Á., Such, E., Arnán, M., Solé, F. G., Díaz‐Beyá, M., Díez‐Campelo, M., Rey, M. D., González, T., et al. (2023) · Cancers · doi:10.3390/cancers15153822 · Cited by 11
Whole-exome sequencing enhances prognostic classification of myeloid malignancies
Ruffalo, M., Husseinzadeh, H. D., Makishima, H., Przychodzen, B. P., Ashkar, M., Koyutürk, M., Maciejewski, J. P., & LaFramboise, T. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.10.003 · Cited by 11
The 5q- Syndrome: Biology and Treatment
Padron, E., Komrokji, R. S., & List, A. F. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0165-1 · Cited by 12
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
Cassanello, G., Pasquale, R., Barcellini, W., & Fattizzo, B. (2022) · Cancers · doi:10.3390/cancers14194941 · Cited by 11
Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
Syed, Y. Y., & Scott, L. J. (2013) · Drugs · doi:10.1007/s40265-013-0071-x · Cited by 11
Histological evaluation of myeloproliferative neoplasms
Fujiwara, H. (2018) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.18006 · Cited by 10
Spliceosomal factor mutations and mis-splicing in MDS
Hershberger, C. E., Daniels, N. J., & Padgett, R. A. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101199 · Cited by 10
The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms
Hussein, S. E., & Loghavi, S. (2022) · Cancers · doi:10.3390/cancers14225690 · Cited by 10
Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects
Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 10
The Progress of Next Generation Sequencing in Assessment of Myeloid Malinancies
Puyan, F. Ö., & Alkan, S. (2018) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2018.2018.1195 · Cited by 10
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Thol, F. R., & Platzbecker, U. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018022434 · Cited by 10
An Evolutionary Approach to Clonally Complex Hematologic Disorders
Schwenger, E., & Steidl, U. G. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0219 · Cited by 10
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
Duarte, F. B., Gonçalves, R. P., Barbosa, M. C., Filho, F. D. R., dos Santos, T. E. D. J., dos Santos, T. N., & de Vasconcelos, P. R. L. (2014) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2014.03.007 · Cited by 10
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Braulke, F., Schulz, X., Germing, U., Schuler, E., Platzbecker, U., Nolte, F., Hofmann, W., Giagounidis, A. A. N., Götze, K. S. S., Lübbert, M., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2983-0 · Cited by 10
Myelodysplastic Syndromes: Dissecting the Heterogeneity
Greenberg, P. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2211 · Cited by 10
Clonal hematopoiesis and bone marrow inflammation
Xie, X., Su, M., Ren, K., Ma, X., Lv, Z., Li, Z., Mei, Y., & Ji, P. (2022) · Translational research · doi:10.1016/j.trsl.2022.11.004 · Cited by 10
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
Muto, T., Walker, C. S., Agarwal, P., Vick, E. J., Sampson, A. M., Choi, K., Niederkorn, M., Ishikawa, C., Hueneman, K. M., Varney, M. E., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282349 · Cited by 9
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
Loiseau, C., Ali, A., & Itzykson, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.014 · Cited by 10
Recent advances in MDS mutation landscape: Splicing and signalling
Follo, M. Y., Pellagatti, A., Ratti, S., Ramazzotti, G., Faenza, I., Fiume, R., Mongiorgi, S., Suh, P., McCubrey, J. A., Manzoli, L., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100673 · Cited by 9
Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome
Hughes, C., Gallipoli, P., & Agarwal, R. (2021) · Pathology · doi:10.1016/j.pathol.2021.01.005 · Cited by 9
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Rahmé, R., Braun, T., Manfredi, J. J., & Fenaux, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041152 · Cited by 9
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mittelman, M., Muus, P., Nimer, S. D., Hellström‐Lindberg, E., Powell, B. L., Guerci‐Bresler, A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0491-2 · Cited by 9
Self-citation
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
Acha, P., Palomo, L., Fuster‐Tormo, F., Xicoy, B., Mallo, M., Manzanares, A., Grau, J., Marcé, S., Granada, I., Rodríguez‐Luaces, M., et al. (2021) · Cancers · doi:10.3390/cancers13040841 · Cited by 9
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery
Roncador, M., Bernard, E., Hasserjian, R. P., Boultwood, J., Elena, C., Gallì, A., Gurnari, C., Mecucci, C., Michaux, L., Mittelman, M., et al. (2025) · Blood · doi:10.1182/blood.2025028619 · Cited by 8
Self-citation
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL
Husby, S., Bæch‐Laursen, C., Eskelund, C. W., Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Räty, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01725-8 · Cited by 8
Role of Bcl‐2 inhibition in myelodysplastic syndromes
Blum, S., Τσιλιμιδός, Γ., Bresser, H., & Lübbert, M. (2022) · International Journal of Cancer · doi:10.1002/ijc.34377 · Cited by 8
Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment
Zhang, X., Lancet, J. E., & Zhang, L. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1037756 · Cited by 8
Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
Feurstein, S. K., Thomay, K., Hofmann, W. A., Buesche, G., Kreipe, H. H., Thol, F. R., Heuser, M., Ganser, A., Schlegelberger, B., & Göhring, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103269 · Cited by 8
Self-citation
PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY
Molteni, A., Ravano, E., Riva, M., Nichelatti, M., Bandiera, L., Crucitti, L., Truini, M., & Cairoli, R. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.015 · Cited by 8
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
Wang, C., & Sallman, D. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000569 · Cited by 8
Emerging immunosuppressive drugs in myelodysplastic syndromes
Epling‐Burnette, P. K., McDaniel, J. M., Wei, S., & List, A. F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.736487 · Cited by 8
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications
Malcovati, L., Ambaglio, I., & Elena, C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000229 · Cited by 8
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency
Arcioni, F., Roncadori, A., Battista, V. D., Tura, S., Covezzoli, A., Cundari, S., & Mecucci, C. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13067 · Cited by 8
Glioblastoma and acute myeloid leukemia: malignancies with striking similarities
Goethe, E. A., Carter, B. Z., Rao, G., & Pemmaraju, N. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2676-5 · Cited by 10
Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes
Wall, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6703-2_18 · Cited by 8
The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes
Steensma, D. P. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.09.009 · Cited by 7
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
Lucero, J. A., Al-Harbi, S., & Yee, K. W. L. (2023) · Current Oncology · doi:10.3390/curroncol30070459 · Cited by 7
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells
Maslah, N., Rety, S., Bonnamy, M., Aguinaga, L., Huynh, T., Parietti, V., Giraudier, S., Fenaux, P., & Cassinat, B. (2024) · Leukemia · doi:10.1038/s41375-024-02281-z · Cited by 7
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes
Kobbe, G., Schroeder, T. A., Rautenberg, C., Kaivers, J., Gattermann, N., Haas, R. R., & Germing, U. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1645004 · Cited by 7

Authors: Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellström-Lindberg, E., & Mufti, G. J.
Affiliations: King's College London (GB)
From the Department of Medicine, Center for Experimental Hematology, and Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden; King's College London School of Medicine, London, United Kingdom; and Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
ORCID: Jädersten, Martin
Saft, Leonie
Smith, Alexander
Kulasekararaj, Austin
Göhring, Gudrun
Schlegelberger, Brigitte
Mufti, Ghulam J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-05-20
Volume: 29
Issue: 15
Pages: 1971-1979
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.31.8576
OpenAlex: W2131256397
Cited by: 463
References: 33
Citations by year: 2026: 10 · 2025: 12 · 2024: 26 · 2023: 23 · 2022: 27 · 2021: 31 · 2020: 27 · 2019: 33 · 2018: 28 · 2017: 37 · 2016: 34 · 2015: 44 · 2014: 38 · 2013: 47 · 2012: 26
FWCI: 28.44
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords: TP53 mutation, myelodysplastic syndrome, del(5q), p53 expression, disease progression, cytogenetic response, clone size, disease heterogeneity
MeSH terms: Adult, Aged, Aged, 80 and over, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Peptide Fragments, Prognosis, Risk, Leukemia, Myeloid, Acute, Genes, p53, Tumor Suppressor Protein p53, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks